Saturday 17 October 2026
Export KRMD’s income statement to Excel — free account
KORU Medical Systems, Inc.
KRMD Healthcare Medical Instruments & Supplies
KORU Medical Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.1 million, up 22.2% from fiscal 2024. In the quarter to June 2026, revenue grew 18.2%, EPS grew 222.2%, free cash flow grew 26.2% and total debt fell 50.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
3.00
0.03
−0.99%
Follow KRMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.29 | 4.63 | 6.52 | 4.53 | |
P/FCF ratio |
775.14 | 1,645.82 | 0.00 | 0.00 | |
P/Operating CF |
895.66 | 13,625.60 | 245.11 | 2,707.87 | |
P/B ratio |
10.72 | 11.84 | 15.74 | 10.76 | |
Price to Tangible BV |
11.81 | 12.36 | 16.40 | 11.22 | |
EV/Sales |
4.11 | 4.43 | 6.31 | 4.32 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
133.24 | 268.09 | 561.32 | 549.31 | |
EV/FCF |
742.24 | 1,574.16 | (532.53) | (992.05) | |
Quick Ratio |
2.00 | 1.70 | 1.88 | 1.78 | |
Current Ratio |
2.72 | 2.33 | 2.44 | 2.48 | |
Net Debt/EBITDA |
(9.82) | 13.07 | 23.90 | 12.59 | |
Debt/Assets |
0.26% | 0.16% | 0.28% | 0.43% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | |
Asset Turnover |
1.69 | 1.55 | 1.48 | 1.43 | |
Operating CF/Net income |
0.86 | (0.02) | (2.25) | (0.08) | |
Capex/Depreciation |
(2.75) | (0.46) | (2.35) | (0.26) | |
Research and Development Expense of Revenue |
8.88% | 11.19% | 10.51% | 8.97% | |
Selling, General and Administrative Expense of Revenue |
49.31% | 55.95% | 55.44% | 57.63% | |
Intangible Assets out of Total Assets |
0.06 | 0.02 | 0.02 | 0.03 | |
Share Based Compensation of Revenue |
3.80% | 5.79% | 8.93% | 6.03% | |
Graham Net Nets |
0.05 | 0.04 | 0.03 | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.06%) | (1.26%) | (1.11%) | (2.21%) | |
Free Cash Flow Yield |
0.13% | 0.06% | (0.18%) | (0.10%) | |
Revenue per Share |
0.26 | 0.25 | 0.24 | 0.23 | |
Operating CF per Share |
0.00 | 0.00 | 0.02 | 0.00 | |
Capex per Share |
(0.01) | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.01) | 0.00 | 0.01 | 0.00 | |
Cash per Share |
0.18 | 0.19 | 0.19 | 0.18 | |
Shareholders Equity per Share |
0.39 | 0.37 | 0.37 | 0.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.39 | 0.37 | 0.37 | 0.36 | |
Free Cash Flow |
(0.36) | (0.08) | 0.67 | 0.01 | |
Working Capital |
12.33 | 11.74 | 11.79 | 11.59 | |
Capital Expenditures |
(0.58) | (0.09) | (0.42) | (0.05) | |
Net Current Asset Value |
9.60 | 8.92 | 8.84 | 8.78 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.01 | 0.04 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.59 | 6.29 | 6.26 | 5.38 | |
Average Payables |
2.00 | 2.32 | 1.96 | 1.77 | |
Average Inventory |
4.23 | 3.88 | 3.24 | 4.17 | |
Average Assets |
26.74 | 27.90 | 27.71 | 27.25 | |
Average Common Equity |
17.29 | 16.63 | 16.93 | 17.10 |
Columns are period end dates